388 related articles for article (PubMed ID: 24742384)
21. [Synthesis and activity of some new histone deacetylases inhibitors].
Cheng YH; Guo YS; Han HZ; Wang N; Zhang GH; Guo ZR; Wu S
Yao Xue Xue Bao; 2010 Jun; 45(6):735-41. PubMed ID: 20939182
[TBL] [Abstract][Full Text] [Related]
22. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
25. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
28. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
29. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
30. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents.
Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
[TBL] [Abstract][Full Text] [Related]
37. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Taddei M; Cini E; Giannotti L; Giannini G; Battistuzzi G; Vignola D; Vesci L; Cabri W
Bioorg Med Chem Lett; 2014 Jan; 24(1):61-4. PubMed ID: 24345446
[TBL] [Abstract][Full Text] [Related]
38. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
39. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
